https://www.thebody.com/health/hiv-odefsey-ftc-rilpivirine-taf
HIV MedicationsOdefsey

Odefsey for HIV Treatment: Everything You Need to Know

illustration of larger-than-life Odefsey bottle alongside a person holding a massive Odefsey pill
Lily Fulop

    Frequently Asked QuestionsOdefsey

    What is Odefsey used for?

    Odefsey is a complete single-tablet regimen used for the treatment of HIV. It was approved for use by the U.S. Food and Drug Administration in 2016.

    What are the drugs in Odefsey?

    Odefsey contains three medications: rilpivirine (RPV), tenofovir alafenamide (TAF), and emtricitabine (FTC).

    • RPV is in the class of drugs called NNRTIs (short for “non-nucleoside reverse transcriptase inhibitors”), which stop HIV from making copies of itself.
    • TAF and FTC are both in the class of drugs called NRTIs (short for “nucleoside reverse transcriptase inhibitors”), which also block HIV from making copies of itself.

    Can Odefsey be used for any other conditions besides HIV treatment?

    Yes: Because it contains the two medications that make up Descovy (TAF and FTC), Odefsey can be a good fit for people living with HIV who also have hepatitis B. Check with your physician to make sure you have been vaccinated or tested for hepatitis B before you stop or start taking Odefsey.

    How often is Odefsey taken?

    Odefsey is normally taken by mouth once a day, with a meal. Try to take it at the same time every day.

    Does Odefsey have any side effects I should worry about?

    Odefsey is usually very well tolerated. In clinical studies, the most common side effects were headache and difficulty sleeping. In earlier clinical trials of RPV (brand name Edurant), the most common side effects were depression, headache, insomnia, and rash. You should tell your medical provider if you develop any side effects.

    Michael Broder

    Michael Broder

    Michael H. Broder is a same-sex-married, HIV-positive man of learning and letters living in Bed-Stuy, Brooklyn. He holds a PhD in classics from CUNY and an MFA in creative writing from NYU. His book of poems, This Life Now (A Midsummer Night's Press, 2014), was a finalist for a Lambda Literary Award. He is the publisher of Indolent Books, a small nonprofit poetry press, and founder of the HIV Here & Now poetry project.